Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-02-26
- Last Posted Date
- 2012-02-07
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Registration Number
- NCT00006108
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States
Capecitabine in Treating Patients With Malignant Mesothelioma
- First Posted Date
- 2004-02-25
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 27
- Registration Number
- NCT00004183
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States
🇺🇸University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00003867
- Locations
- 🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT00077363
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
- Conditions
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- Daiichi Sankyo
- Registration Number
- NCT00077077
- Locations
- 🇺🇸
Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Cancer Therapy and Research Center, San Antonio, Texas, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer
- Conditions
- First Posted Date
- 2004-02-03
- Last Posted Date
- 2012-07-18
- Target Recruit Count
- 15
- Registration Number
- NCT00008034
- Locations
- 🇨🇭
Hopital Cantonal Universitaire de Geneva, Geneva, Switzerland
Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma
- Conditions
- First Posted Date
- 2004-01-28
- Last Posted Date
- 2007-03-28
- Lead Sponsor
- PhytoCeutica
- Target Recruit Count
- 31
- Registration Number
- NCT00076609
- Locations
- 🇨🇳
National Institute of Cancer Research, Taipei, Taiwan
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸VA Connecticut Cancer Center, West Haven, Connecticut, United States
Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma
- Conditions
- Locations
- 🇫🇷
Hopital Tenon, Paris, France
🇫🇷Hopital Drevon, Dijon, France
🇫🇷Centre Regional Francois Baclesse, Caen, France
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 84
- Registration Number
- NCT00074321
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT00070252
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of Wisconsin Medical School, Milwaukee, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.